This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Biology Research program (CFDA 93.396), provides $683,979 to Weill Medical College of Cornell University to conduct research on the role of early oncogenic drivers in maintaining lineage fidelity in prostate cancer. The overall objective is to define the propensity of prostate cancers harboring SPOP mutations to progress to specific subtypes of treatment-resistant castration-resistant prostate cancer...
This federal Project Grant award of $564,543 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research at Weill Medical College of Cornell University to investigate the role of the androgen receptor (AR) in prostate cancer. The key objectives are to: Determine the conditions that allow the growth-suppressive AR transcriptional programs to be reactivated in prostate cancer cells. Establish the clinical implications of oncogenic versus...
The National Cancer Institute (NCI) awarded a Project Grant (CFDA 93.395 - Cancer Treatment Research) to New York University School of Medicine in the amount of $624,001.00 on August 1, 2024. The grant funds research to develop a novel class of molecules called Multivalent Peptoid Conjugates (MPCs) that can potently stop the growth of prostate cancer cells resistant to standard anti-androgen treatments. The research aims to identify how MPCs antagonize the androgen receptor and promote a...
The National Cancer Institute (NCI) awarded a $1,408,844 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the Sloan-Kettering Institute for Cancer Research in New York, NY. The grant, effective July 2, 2024 through June 30, 2028, supports research to characterize the theranostic potential of Delta-Like Ligand 3 (DLL3)-targeting agents for the diagnosis and treatment of high-grade neuroendocrine carcinomas of the lung (small cell lung cancer) and prostate (neuroendocrine prostate...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) in the amount of $702,748 will fund research to determine the role of neutrophils in anti-tumor immunity and immune-related adverse events in the context of T cell-based cancer therapies. The award, which runs from March 2025 to January 2030, will support three key aims: Characterizing the gene pathways and tumor-derived factors that define functional subsets of anti-tumorigenic...
This $194,778 Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) supports the Weill Medical College of Cornell University in optimizing strategies to improve National Cancer Institute-sponsored clinical trial participation throughout the Weill Cornell Medicine - Meyer Cancer Center sphere across New York City. The primary goals are to expand access to and participation in NCI-sponsored clinical trials, particularly among diverse and underserved patient...
The National Cancer Institute (NCI), under the Federal Grant Program for Cancer Biology Research (CFDA 93.396), awarded a $2,561,215 Project Grant to Weill Medical College of Cornell University. The grant, effective from August 12, 2024, through July 31, 2029, supports research to investigate the epigenetic basis and therapeutic targeting of the unique lymphoma immunological niche. The research team will address key hypotheses related to the role of chromatin, cell-intrinsic and cell-extrinsic...
The National Cancer Institute (NCI) awarded a $108,512 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to Weill Medical College of Cornell University. The grant, effective March 1, 2025, will support research aimed at investigating the chromatin landscape and its impact on Alternative Lengthening of Telomeres (ALT) in cancer cells. The key objectives are to: 1) Determine the role of the chromatin remodeler ATRX in suppressing ALT, and 2) Examine how H3K9 methylation at...
The National Cancer Institute (NCI) awarded a $145,336 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Sloan-Kettering Institute for Cancer Research. The grant, with a performance period from March 1, 2025 to February 28, 2027, will support research to metabolically reprogram hepatic macrophages to overcome the "immune-desert" phenotype of B-catenin-driven hepatocellular carcinoma. The project aims to determine how TSC1-deficient hepatic macrophages can...
The National Cancer Institute (NCI) awarded a Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Sloan-Kettering Institute for Cancer Research. The $256,487 grant, effective August 13, 2024, supports a 5-year research project to develop multimodal predictive models for non-small cell lung cancer (NSCLC) using real-world data sources such as circulating tumor DNA sequencing, tumor genomics, and clinician notes. The goal is to improve risk stratification and clinical...
The National Cancer Institute (NCI) awarded a $785,900 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to Weill Medical College of Cornell University. The 3-year grant, effective July 1, 2024, will fund research to investigate the drivers of tumor heterogeneity and the progression to neuroendocrine prostate cancer (NEPC). The research leverages a novel mouse model and organoid-based platform to modulate the expression of a key transcriptional regulator, assess NEPC sensitivity to treatments, and evaluate how targeting epigenetic modifiers impacts tumor subpopulations and therapeutic resistance. The award will also support the grant recipient's continued career development through workshops, coursework, and attendance at scientific conferences to enhance their expertise in single-cell bioinformatics and exposure to clinical barriers in prostate cancer.